| Project/Area Number |
16209053
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Functional basic dentistry
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
OHYA Keiichi Tokyo Medical and Dental University, Graduate School, Hard Tissue Engineering/Pharmacology, Professor, 大学院医歯学総合研究科, 教授 (10126211)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIMOKAWA Hitoyata Tokyo Medical and Dental University, Graduate School, Hard Tissue Engineering/Pharmacology, Associate Professor, 大学院医歯学総合研究科, 助教授 (80014257)
AOKI Kazuhiro Tokyo Medical and Dental University, Graduate School, Hard Tissue Engineering/Pharmacology, Assistant, 大学院医歯学総合研究科, 助手 (40272603)
TAKAHASHI Mariko Tokyo Medical and Dental University, Faculty of Dentistry, Academic Staff, 歯学部, 教務職員 (90334440)
|
|---|
| Project Period (FY) |
2004 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥48,620,000 (Direct Cost: ¥37,400,000、Indirect Cost: ¥11,220,000)
Fiscal Year 2006: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2005: ¥14,950,000 (Direct Cost: ¥11,500,000、Indirect Cost: ¥3,450,000)
Fiscal Year 2004: ¥28,340,000 (Direct Cost: ¥21,800,000、Indirect Cost: ¥6,540,000)
|
|---|
| Keywords | bone resorption / periodontitis / osteoclasts / Rheumatoid Arthritis / TNF / RANKL / Nano-gel / Mini-pump / RANK / NF-kβ / 骨粗鬆症 |
|---|
| Research Abstract |
The aim of this study is to develop newly drug molecules that act as bone resorption inhibitors and to make hybrid type drugs with new molecules and the pre-existed drugs or the delivery materials. The following results were obtained.
・The newly developed small peptide, WP9QY, is the antagonist for the TNF-a receptor and shows the activity to inhibit osteoclast formation. WP9QY also inhibit enhanced bone resorption in the animal model such as the low calcium feeding rats, the ovaryectomy rats, the arthritis induced rats and the periodontitis bacteria injected rats. In addition, WP9QY has the anti-inflammatory effects.
・Other than the antagonist for TNF-a receptor, WP9QY prevents the RANK-RANKL interaction and acts as an antagonist. WP9QY interferes the RANK-RANKL through its binding to the receptor-ligand complex and changing the conformation of the complex.
・Newly synthesized peptide, NBD, blocks the movement of NF-kB to the nucleus and interferes the proliferation and differentiation of osteoclasts. It also shows the inhibitory effects on bone resorption in various animal model for bone resorption.
・The hybrid molecule combined with CHP-nanogel and WP9QY peptide improves the stability of the peptide in the body and releases peptide slowly. The hybrid molecule inhibited bone resorption more efficiently than peptide itself in various animal model for bone resorption.
Form these results, the new drugs that target the cytokine receptor or the signal transduction system in osteoclasts seems to contribute the development of therapeutic regimen for bone resorption inhibitors. Moreover the hybrid molecules with hydrogel scaffolds and new drugs improve the stability and efficacy of drugs and these hybrid molecules may serve as a more potent drugs that inhibit bone resorption.
|
